TROP-2 and 5hmC expression in follicular-patterned thyroid neoplasm emphasizing tiny well-formed papillae
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seok, Jae Yeon | - |
dc.contributor.author | Fan, Xuemo | - |
dc.date.accessioned | 2022-06-13T00:40:12Z | - |
dc.date.available | 2022-06-13T00:40:12Z | - |
dc.date.created | 2022-02-07 | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 1092-9134 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84615 | - |
dc.description.abstract | Background: Follicular-patterned thyroid neoplasms (FPTNs), characterized by predominantly follicular growth pattern, represent diverse pathological entities. We aimed to study the nuclear features and the immunoexpression of trophoblast cell-surface antigen 2 (TROP-2) and 5-hydroxymethylcytosine (5hmC) in FPTNs. Design: FPTNs were divided into 4 groups: I) noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), II) encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) with capsular invasion, III) infiltrative FVPTC, and IV) PTC with a predominantly follicular pattern and well-formed papillae (<1%). Nuclear characteristics were evaluated by image analysis. TROP-2 and 5hmC immunostains were analyzed correlating with histological features using QuPath. Results: From the group I to II, III, and IV, there is a gradual increase in nuclear atypia in terms of the nuclear area, max caliper, perimeter, circularity, and hematoxylin OD means (corresponding to nuclear enlargement, membrane irregularity, and clearing). A similar trend is observed in the TROP-2 expression. 5hmC expression is highly preserved in groups I, II, and III in contrast to a significant loss in group IV. Group IV tumors show more frequent regional lymph node involvement and the highest BRAF V600E mutation rate. Conclusion: Among FPTNs, group IV tumors exhibit the most advanced nuclear atypia, highest TROP-2 expression, significant 5HMC expression loss, frequent regional lymph node involvement, and the highest BRAF V600E mutation rate. Our data further support that the presence of any true papillae should be an exclusion criterion for NIFTP. Therefore, well-formed papillae even if very minute (<1% of the tumor) should not be overlooked. © 2022 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.isPartOf | Annals of Diagnostic Pathology | - |
dc.title | TROP-2 and 5hmC expression in follicular-patterned thyroid neoplasm emphasizing tiny well-formed papillae | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000804031400006 | - |
dc.identifier.doi | 10.1016/j.anndiagpath.2022.151903 | - |
dc.identifier.bibliographicCitation | Annals of Diagnostic Pathology, v.57 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85123858702 | - |
dc.citation.title | Annals of Diagnostic Pathology | - |
dc.citation.volume | 57 | - |
dc.contributor.affiliatedAuthor | Seok, Jae Yeon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | 5hmC | - |
dc.subject.keywordAuthor | Follicular | - |
dc.subject.keywordAuthor | NIFTP | - |
dc.subject.keywordAuthor | Papillary carcinoma | - |
dc.subject.keywordAuthor | Thyroid gland | - |
dc.subject.keywordAuthor | TROP-2 | - |
dc.subject.keywordPlus | NUCLEAR FEATURES | - |
dc.subject.keywordPlus | VARIANT | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | CRITERIA | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.